Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 347 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the transaction, the insider now directly owns 10,438 shares of the company’s stock, valued at approximately $3,499,235.12. This represents a 3.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Madrigal Pharmaceuticals Price Performance

MDGL stock opened at $310.92 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The business has a 50-day simple moving average of $314.37 and a two-hundred day simple moving average of $273.95. The company has a market capitalization of $6.78 billion, a P/E ratio of -12.40 and a beta of -0.36. Madrigal Pharmaceuticals, Inc. has a 52-week low of $168.25 and a 52-week high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.94) by $2.02. The company had revenue of $62.18 million for the quarter, compared to analysts’ expectations of $34.60 million. During the same period in the previous year, the firm earned ($5.34) EPS. Research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.55 EPS for the current fiscal year.

Analysts Set New Price Targets

MDGL has been the subject of several recent research reports. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. Oppenheimer dropped their price target on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. HC Wainwright lifted their target price on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $351.67.

Institutional Trading of Madrigal Pharmaceuticals

Several institutional investors have recently made changes to their positions in MDGL. Braidwell LP purchased a new position in Madrigal Pharmaceuticals during the third quarter worth about $39,010,000. Eagle Asset Management Inc. bought a new position in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $6,875,000. Intech Investment Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the third quarter valued at approximately $1,280,000. Vestal Point Capital LP bought a new stake in Madrigal Pharmaceuticals during the third quarter worth $6,367,000. Finally, Blueshift Asset Management LLC purchased a new position in Madrigal Pharmaceuticals in the third quarter worth $393,000. Institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.